Rivera D - EpiVax, Inc. - Informatics and Immunology

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

by epivax3 | Oct 22, 2016

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein Scios Inc, Brown University, Amgen Clinical Immunology (2007). [ISPRI prediction of immunogenicity]

HIV vaccine development by computer assisted design: the GAIA vaccine

by epivax3 | Oct 22, 2016

Vaccine. 2005 Mar 18; 23 [7-18):2136-48.

Developing an epitope-driven tuberculosis (TB) vaccine

by epivax3 | Oct 22, 2016

Vaccine. 2005 Mar 18; 23(17-18):2121-31.

Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island

by epivax3 | Oct 22, 2016

Human Vaccines 2006 June; 2(3), 119-128.

Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

by epivax3 | Oct 22, 2016

Vaccine. 2007 Apr 20;25(16):3179-91.

Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein

HIV vaccine development by computer assisted design: the GAIA vaccine

Developing an epitope-driven tuberculosis (TB) vaccine

Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island

Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

Recent Posts

Categories